The FDA attended a World Health Organization meeting on updating influenza vaccines, reversing a ban by the Trump administration. Exemptions allow FDA collaboration, similar to CDC's role in responding to the Ebola outbreak in Uganda. WHO experts, including Dr. Wenqing Zhang, affirmed the FDA's involvement in the consultation process, crucial for vaccine effectiveness. Major updates include adjusting the H3 strain component of the flu shot, which has shown variable effectiveness, particularly in children. The adaptability of the H3 strain complicates vaccine development, highlighting ongoing public health efforts.
FDA, the same as CDC, participated in the vaccine composition consultation that just finished. They contributed again with the data package.
One major change recommended by the WHO for the next flu season is an update to an ingredient that guards against strains of the virus called H3.
Collection
[
|
...
]